Jason V Coloma, Chief Executive Officer and Director of Maze Therapeutics, Inc. (NASDAQ:MAZE), filed a Form 4 on September 3, 2026, disclosing share disposals and a restricted stock unit settlement that occurred on September 1, 2026.

Key Highlights

  • RSU settlement: 50,000 restricted stock units were converted to 50,000 shares of Common Stock at $0 cost on September 1, 2026, held directly.
  • Trust sale (Coloma 2021 Irrevocable Trust): 2,593 shares disposed at a weighted average price of $26.307, with individual transactions ranging from $26.14 to $26.50 per share.
  • Trust sale (Coloma Family Trust): 31,908 shares disposed at a weighted average price of $26.2876, with individual transactions ranging from $26.13 to $26.555 per share.
  • Post-transaction holdings: 18,151 shares held indirectly through The Coloma 2021 Irrevocable Trust; 223,355 shares held indirectly through the Coloma Family Trust; 50,000 shares held directly.
  • Rule 10b5-1 plan: Both sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
  • Remaining RSUs: 50,000 restricted stock units remain directly held following the transaction.

Coloma's September 2026 Transactions: RSU Vest, Trust Sales, and Post-Transaction Positions

According to the filing, Jason V Coloma serves as both Chief Executive Officer and Director of Maze Therapeutics, Inc. On September 1, 2026, the reporting person recorded three transactions in Maze Therapeutics Common Stock. The first was the vesting and settlement of 50,000 restricted stock units (transaction code M), converting to 50,000 shares of Common Stock at $0 exercise price, held directly. The filing notes that the award vests as to 1/2 of the total on September 1, 2026 and September 1, 2027, subject to continued service to the issuer on each vesting date, and that these RSUs do not expire but either vest or are cancelled prior to the vesting date.

The two sales disclosed in the filing were each conducted under transaction code S and, according to the filing, were "effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026." The first sale involved 2,593 shares disposed from The Coloma 2021 Irrevocable Trust, for which the reporting person and his spouse serve as co-trustees, at a weighted average price of $26.307, with actual per-share prices ranging from $26.14 to $26.50. The second sale involved 31,908 shares disposed from the Coloma Family Trust, also co-trusteed by the reporting person and his spouse, at a weighted average price of $26.2876, with actual per-share prices ranging from $26.13 to $26.555.

After all reported transactions, the filing discloses that Coloma beneficially owns 18,151 shares indirectly through The Coloma 2021 Irrevocable Trust, 223,355 shares indirectly through the Coloma Family Trust, and 50,000 shares directly. On the derivative side, 50,000 restricted stock units remain directly held following the settlement of the 50,000-unit tranche. The filing was signed by Courtney Phillips as attorney-in-fact on September 3, 2026.

What Was Disclosed

The filing reports a September 1, 2026 RSU settlement of 50,000 shares and two trust-held share sales totaling 34,501 shares under a pre-established Rule 10b5-1 plan, with resulting beneficial ownership across direct and indirect accounts disclosed for Maze Therapeutics (NASDAQ:MAZE).